The Motley Fool·Sep 1, 2026
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.
Ctrl K
Amylyx Pharmaceuticals has transitioned to a clinical-stage biotech following the voluntary withdrawal of Relyvrio, with zero revenue in 2026Q2 and a 78% sequential cash decline to $49.3M. The company's pipeline, including the PHOENIX trial failure, offers no ...
Price trend, volume and key moving averages
Trailing total returns as of 9/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.39-8.1% vs -$0.36 | — vs — |
Q2 2026 May 7, 2026 | -$0.37-8.8% vs -$0.34 | — vs — |
Q2 2026 Mar 3, 2026 | -$0.30+3.2% vs -$0.31 | — vs $52,000 |
Q4 2025 Nov 6, 2025 | -$0.37+14.0% vs -$0.43 | — vs $52,000 |
Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.
BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company's stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,827,085 shares of the company's stock, valued at approximately $158,534,000. BlackRock Inc. owned approximately 7.94% of Amylyx Pharmaceuticals as
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
Benchmark AMLX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Amylyx Pharmaceuticals, Inc. (AMLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $33.88 | $3.77B | -22.14 | -100% | — | -61.59% | — | |
| $56.71 | $9.42B | -23.83 | 33.87% | -64.64% | -110.84% | — | |
| $212.50 | $31.4B | 24.07 | 1.39% | 8.39% | 4.52% | — | |
| $534.16 | $12.32B | -41.57 | 432.05% | -25.32% | -56.65% | — | |
| $27.58 | $4.72B | 12.04 | 11.87% | 33.42% | 32.39% | — | |
| $9.54 | $499.45M | -2.11 | -92.84% | -80.67% | -14.98% | — |
Amylyx Pharmaceuticals, Inc. (AMLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Amylyx Pharmaceuticals, Inc. (AMLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 4, 2026·SEC
May 7, 2026·SEC
Get notified when AMLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Amylyx Pharmaceuticals, Inc. (AMLX) stock FAQ — growth, dividends, profitability & financials explained
Amylyx Pharmaceuticals, Inc. (AMLX) saw revenue decline by 100.0% over the past year.
Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $152.1M for fiscal year 2025.
Amylyx Pharmaceuticals, Inc. (AMLX) has a return on equity (ROE) of -61.6%. Negative ROE indicates the company is unprofitable.
Amylyx Pharmaceuticals, Inc. (AMLX) had negative free cash flow of $126.7M in fiscal year 2025, likely due to heavy capital investments.
